GLP-2 formulations

Details GLP-2 formulations GLP-2 formulations

2006-06-06

2006-06-06

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S308000, C530S399000, C530S324000, C435S004000, C435S287100

Reexamination Certificate

active

07056886

ABSTRACT:
The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and mannitol.

REFERENCES:
patent: 4985244 (1991-01-01), Makino et al.
patent: 5652216 (1997-07-01), Kornfelt et al.
patent: 5912229 (1999-06-01), Thim et al.
patent: 5952301 (1999-09-01), Drucker
patent: 5997856 (1999-12-01), Hora et al.
patent: 6120761 (2000-09-01), Yamazaki et al.
patent: 97/39031 (1997-10-01), None
patent: 98/03547 (1998-01-01), None
patent: 99/43361 (1999-09-01), None
Buhl et al., Naturally Occurring Products of Proglucagon 111-160 in the Porcine and Human Samll Intestine, J. Biol. Chem. 263, 8621-8624 (1988).
Lund et al., Anglerfish Islet Pre-proglucagon II, Nucleotide and corresponding amino acid Sequenmce of the cDNA, J. Biol. Chem. 258, 3280-3284 (1983).

Affiliated with

Also associated with

Rating

GLP-2 formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GLP-2 formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GLP-2 formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3655291